<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02915861</url>
  </required_header>
  <id_info>
    <org_study_id>MICRO1504</org_study_id>
    <nct_id>NCT02915861</nct_id>
  </id_info>
  <brief_title>Eschar Investigations in Scrub Typhus</brief_title>
  <acronym>EXIST</acronym>
  <official_title>Eschar Investigations to Improve Diagnostics, Understand Early Immune Responses and Characterize Strains for Vaccines in Scrub Typhus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiangrai Prachanukroh Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study of patients with scrub typhus (rapid diagnostic&#xD;
      test/quantitative polymerase chain reaction (RDT/qPCR) positive) and an inoculation eschar&#xD;
      present on examination, recruited from Chiangrai Prachanukroh Hospital, North of Thailand.&#xD;
&#xD;
      In this study, we aim to:&#xD;
&#xD;
        -  Investigate relevant pathogen dissemination dynamics, early innate immune response, and&#xD;
           pathogen-host interactions in scrub typhus using a minimal set of easily accessible&#xD;
           samples; the inoculation eschar (crust or biopsy), whole blood and - where possible - a&#xD;
           lymph node fine-needle aspiration (FNA).&#xD;
&#xD;
        -  Determine the potential use of the inoculation eschar for improving early diagnostics&#xD;
           and assessing the diversity of human pathogenic strains; by evaluating non-invasive&#xD;
           swabs and scrapings, as well as biopsies for molecular diagnostics templates.&#xD;
&#xD;
        -  Dissect the underlying patho-biology associated with the inoculation eschar and in a&#xD;
           subgroup, including the draining lymph node; by defining the spectrum of infected cells&#xD;
           via microscopy and double-immune labeling; by determining cytokine and RNA gene&#xD;
           expression profiles in blood peripheral blood mononuclear cell (PBMCs) and eschar&#xD;
           samples.&#xD;
&#xD;
      Data sharing:&#xD;
&#xD;
      No future analysis or study of legacy data/specimens including data sharing for purposes not&#xD;
      specified in the protocol will be done without seeking further regulatory (EC/IRB) approval&#xD;
&#xD;
        -  Any requests for data sharing will be considered by MORU's data sharing committee&#xD;
&#xD;
        -  Any data subsequently shared will be anonymised and will not include personal&#xD;
           identifiers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scrub typhus patients will be recruited into the scrub typhus patient (EXP) arm of the study.&#xD;
      There will be 3 sub-groups:&#xD;
&#xD;
        -  EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study,&#xD;
           declined biopsy).&#xD;
&#xD;
        -  EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected&#xD;
           (consent to study, draining lymph node (LN) inaccessible).&#xD;
&#xD;
        -  EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA&#xD;
           collected (consent to study, draining LN accessible).&#xD;
&#xD;
      Samples will be collected at baseline (all) and 2 weeks (blood only).&#xD;
&#xD;
      Control participants will be recruited into the scrub typhus control.&#xD;
&#xD;
      - EXC (n=12) are healthy individuals, attending hospital for elective/minor surgery or&#xD;
      treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood&#xD;
      and a skin sample will be collected at baseline only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotypic characterisation of the major subset of Orientia tsutsugamushi (OT) infected leucocytes within eschar, lymph node, and blood during the dissemination phase of OT in vivo.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterisation of cytokine and RNA gene expression profiles within the eschar, lymph node, and blood in vivo and comparisons with profiles of uninfected target cells.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishing the usefulness of non-invasive eschar samples from patients with acute scrub typhus for diagnostics for OT and for genotyping +/- whole-genome sequencing.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define and contrast the eschar histo-pathological findings in this study in Thailand to previous findings from Laos, where the Gilliam strain predominates.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons to parallel studies in the non-human primate model with emphasis on dissemination dynamics, immunomodulation, and the innate and adaptive immune responses to OT; contributing to vaccine development.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">44</enrollment>
  <condition>Scrub Typhus</condition>
  <arm_group>
    <arm_group_label>EXPa</arm_group_label>
    <description>Scrub typhus patients: Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPb</arm_group_label>
    <description>Scrub typhus patients: Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPc</arm_group_label>
    <description>Scrub typhus patients: Group C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXC</arm_group_label>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-invasive eschar samples + blood</intervention_name>
    <description>EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).</description>
    <arm_group_label>EXPa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-invasive eschar samples+eschar biopsy+blood</intervention_name>
    <description>EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).</description>
    <arm_group_label>EXPb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood</intervention_name>
    <description>EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).</description>
    <arm_group_label>EXPc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood+Skin sample</intervention_name>
    <description>Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.</description>
    <arm_group_label>EXC</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Non-invasive eschar samples&#xD;
&#xD;
        2. Eschar biopsy&#xD;
&#xD;
        3. Lymph node fine-needle aspiration biopsy (LN FNA)&#xD;
&#xD;
        4. Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        EXP: Male and female patients ≥7 years old with confirmed acute scrub typhus and an eschar&#xD;
        present on examination (N=36).&#xD;
&#xD;
        EXC: Healthy individuals ≥7 years old who normally reside in a scrub typhus endemic region,&#xD;
        attending hospital for elective/minor surgery or treatment of minor skin injury, and&#xD;
        preferably age and sex-matched (N=12).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Scrub Typhus Patients (EXP) inclusion criteria:&#xD;
&#xD;
          -  Age ≥7 years old.&#xD;
&#xD;
          -  Presentation to hospital with fever in ≤14 days and a clinical suspicion of typhus.&#xD;
&#xD;
          -  Eschar observed on examination.&#xD;
&#xD;
          -  Scrub typhus RDT positive or OT qPCR positive (if qPCR available at local site by time&#xD;
             of study initiation).&#xD;
&#xD;
          -  Willingness to participate in the study. Written informed consent obtained from the&#xD;
             patient (≥18 years old) or, written informed assent from participant (≥7 to &lt;18years&#xD;
             old) along with written informed consent from participant's parent(s)/legal&#xD;
             guardian(s).&#xD;
&#xD;
        Scrub Typhus Controls (EXC) inclusion criteria:&#xD;
&#xD;
          -  Age ≥7 years old.&#xD;
&#xD;
          -  Clinically well, attending elective/minor surgery or for treatment of minor skin&#xD;
             injury.&#xD;
&#xD;
          -  Historical diagnosis of scrub typhus (RDT, serology, and/or PCR positivity) more than&#xD;
             2 years ago or living in an endemic area with high risk of previous exposure.&#xD;
&#xD;
          -  Willingness to participate in the study. Written informed consent obtained from the&#xD;
             patient (≥18 years old) or written informed assent from participant (≥7 to &lt;18years&#xD;
             old) along with written informed consent from participant's parent(s)/legal&#xD;
             guardian(s).&#xD;
&#xD;
        Scrub Typhus Patients (EXP) exclusion criteria:&#xD;
&#xD;
          -  Current TB or TB treatment in ≤6 months (contains OT-effective antimicrobials)&#xD;
&#xD;
          -  Documented HIV infection, use of steroids, chemotherapy, other immunosuppressants, or&#xD;
             herbal remedies containing steroids, and/or pregnancy&#xD;
&#xD;
        Scrub Typhus Controls (EXC) exclusion criteria:&#xD;
&#xD;
          -  Significant acute intercurrent illness at the time of admission including fever&#xD;
             &gt;37.5˚C or infection (including TB) requiring antibiotics&#xD;
&#xD;
          -  Documented HIV infection, use of steroids, chemotherapy, other immunosuppressants, or&#xD;
             herbal remedies containing steroids, and/or pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Tri Wangrangsimakul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiangrai Prachanukroh Hospital, Chiangrai, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune responses</keyword>
  <keyword>vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhus, Epidemic Louse-Borne</mesh_term>
    <mesh_term>Scrub Typhus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

